A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients with Type 2 Diabetes

Exclusion Criteria

• - Have previously received exenatide or glucagon-like peptide-1
• analogs.
• - Have participated in an interventional medical, surgical, or
• pharmaceutical study (a study in which an experimental, drug,
• medical, or surgical treatment was given) within 30 days of screening.
• This criterion includes drugs that have not received regulatory
• approval for any indication at the time of study entry.
• - Receiving beta blockers.
• - Receiving treatment with a drug directly affecting gastrointestinal motility, including but not limited to Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.
• - Have received treatment with systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route within 6 weeks of screening, or are regularly treated with potent, inhaled intranasal steroids that are known to have a high rate of systemic absorption or bronchodilators.
• - Have been treated with drugs that promote weight loss (for example, Adipex® [phentermine], Acomplia® [rimonabant], Xenical® [orlistat], Meridia® [sibutramine], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
• - Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: *Insulin; *Alpha-glucosidase inhibitors (for example, Glyset® [miglitol] or Precose® [acarbose]); *Meglitinides (for example, Prandin® [repaglinide] or Starlix® [nateglinide]); *Sulfonylureas (for example, Glucotrol® [glipizide] or Micronase® [glyburide]); *Dipeptidyl peptidase IV (DPP-IV) inhibitors (for example, Januvia™ [sitagliptin])
• - Have donated blood within 60 days of screening.